Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)
Rakesh Popat(University College London Hospitals NHS Foundation Trust), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Shirley D’Sa(University College Hospital), Neil Rabin(University College London), Nicholas Counsell(University College London), Mickey Koh(St George's Hospital), James D. Cavenagh(National Health Service), Gordon Cook(University of Leeds), Alison Evans(Cancer Research UK), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Toyin Adedayo(Cancer Research UK), Mark Cook(Université Paris Cité), Matthew Streetly(King's College - North Carolina), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Janet lyons-Lewis(University College London Hospitals NHS Foundation Trust), Josephine Crowe(Royal United Hospital), Paul Smith(Cancer Research UK), Stephen Schey(University College Hospital), Andres Virchis(The Royal Free Hospital), Michael F. Quinn(University of Ulster), Nivette Braganca(Cancer Research UK), Charles Crawley(Addenbrooke's Hospital), Heather Oakervee(Barts Health NHS Trust)
Cited by 1
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695